Testosterone replacement elevates the serum uric acid levels in patients with female to male gender identity disorder
-
- Kurahashi Hiroaki
- Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan
-
- Watanabe Masami
- Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama University, Okayama, Japan
-
- Sugimoto Morito
- Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan
-
- Ariyoshi Yuichi
- Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan
-
- Mahmood Sabina
- Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama University, Okayama, Japan
-
- Araki Motoo
- Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan
-
- Ishii Kazushi
- Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan
-
- Nasu Yasutomo
- Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama University, Okayama, Japan
-
- Nagai Atsushi
- Department of Urology, Kawasaki Medical School, Kurashiki, Japan
-
- Kumon Hiromi
- Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan
この論文をさがす
抄録
Gender identity disorder (GID) results from a disagreement between a person’s biological sex and the gender to which he or she identifies. With respect to the treatment of female to male GID, testosterone replacement therapy (TRT) is available. The uric acid (UA) level can be influenced by testosterone; however, the early effects and dose-dependency of TRT on the serum UA concentration have not been evaluated in this population. We herein conducted a dose-response analysis of TRT in 160 patients with female to male GID. The TRT consisted of three treatment groups who received intramuscular injections of testosterone enanthate: 125 mg every two weeks, 250 mg every three weeks and 250 mg every two weeks. Consequently, serum UA elevation was observed after three months of TRT and there was a tendency toward testosterone dose-dependency. The onset of hyperuricemia was more prevalent in the group who received the higher dose. We also demonstrated a positive correlation between increased levels of serum UA and serum creatinine. Since the level of serum creatinine represents an individual’s muscle volume and the muscle is a major source of purine, which induces UA upregulation, the serum UA elevation observed during TRT is at least partially attributed to an increase in muscle mass. This is the first study showing an association between serum UA elevation and a TRT-induced increase in muscle mass. The current study provides important information regarding TRT for the follow-up and management of the serum UA levels in GID patients.
収録刊行物
-
- Endocrine Journal
-
Endocrine Journal 60 (12), 1321-1327, 2013
一般社団法人 日本内分泌学会